{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:27:07Z","timestamp":1792708027736,"version":"4.5.0"},"reference-count":144,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Bullous pemphigoid (BP) is one of the most common autoimmune bullous diseases and mainly affects an elderly population with multi-morbidity. Due to the frailty of many BP patients, existing treatment options are limited. The blisters associated with BP result from IgG and IgE autoantibodies binding to the central components of hemidesmosome, BP180, and BP230, stimulating a destructive inflammatory process. The known characteristic features of BP, such as intense pruritus, urticarial prodrome, peripheral eosinophilia, elevated IgE, as well as recent expanding evidence from <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> studies implicate type 2 inflammation as an important driver of BP pathogenesis. Type 2 inflammation is an inflammatory pathway involving a subset of CD4+ T cells that secrete IL-4, IL-5, and IL-13, IgE-secreting B cells, and granulocytes, such as eosinophils, mast cells, and basophils. It is believed that effectors in type 2 inflammation may serve as novel and effective treatment targets for BP. This review focuses on recent understandings of BP pathogenesis with a particular emphasis on the role of type 2 inflammation. We summarize current clinical evidence of using rituximab (B-cell depletion), omalizumab (anti-IgE antibody), and dupilumab (anti-IL-4\/13 antibody) in the treatment of BP. The latest advances in emerging targeted therapeutic approaches for BP treatment are also discussed.<\/jats:p>","DOI":"10.3389\/fmed.2023.1196946","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T11:03:25Z","timestamp":1691492605000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Targeting type 2 inflammation in bullous pemphigoid: current and emerging therapeutic approaches"],"prefix":"10.3389","volume":"10","author":[{"given":"Wu Han","family":"Toh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-En","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Bing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.3389\/fimmu.2019.01506","article-title":"New Insights Into the Pathogenesis of Bullous Pemphigoid: 2019 Update","volume":"10","author":"Genovese","year":"2019","journal-title":"Front Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jaad.2019.04.029","article-title":"Nonbullous pemphigoid: Insights in clinical and diagnostic findings, treatment responses, and prognosis","volume":"81","author":"Lamberts","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1001\/jamadermatol.2018.4390","article-title":"Assessment of diagnostic strategy for early recognition of bullous and nonbullous variants of pemphigoid","volume":"155","author":"Meijer","year":"2019","journal-title":"JAMA Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/jid.2010.357","article-title":"The relationship between neurological disease and bullous pemphigoid: a population-based case-control study","volume":"131","author":"Langan","year":"2011","journal-title":"J Invest Dermatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jid.2019.11.005","article-title":"Recent Advances in Understanding Pemphigus and Bullous Pemphigoid","volume":"140","author":"Hammers","year":"2020","journal-title":"J Invest Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1111\/jdv.14312","article-title":"Multimorbidity in bullous pemphigoid: a case-control analysis of bullous pemphigoid patients with age- and gender-matched controls","volume":"31","author":"Sim","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fmed.2018.00220","article-title":"The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations","volume":"5","author":"Kridin","year":"2018","journal-title":"Front Med (Lausanne)."},{"key":"B10","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14601","article-title":"Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database","volume":"175","author":"B\u00e9n\u00e9","year":"2016","journal-title":"Br J Dermatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/jamadermatol.2018.2352","article-title":"Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients","volume":"154","author":"Kridin","year":"2018","journal-title":"JAMA Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.jid.2018.11.025","article-title":"Gliptin-associated bullous pemphigoid: a valuable model of the mechanism of breakdown of immune tolerance against BP180","volume":"139","author":"Nishie","year":"2019","journal-title":"J Invest Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/1346-8138.15195","article-title":"Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan","volume":"47","author":"Hung","year":"2020","journal-title":"J Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3389\/fimmu.2019.01238","article-title":"Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid","volume":"10","author":"Tasanen","year":"2019","journal-title":"Front Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s12020-020-02272-x","article-title":"Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials","volume":"69","author":"Silverii","year":"2020","journal-title":"Endocrine."},{"key":"B16","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jamadermatol.2020.1587","article-title":"Association between medication use and bullous pemphigoid: a systematic review and meta-analysis","volume":"156","author":"Liu","year":"2020","journal-title":"JAMA Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1001\/jamadermatol.2022.1624","article-title":"Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review","volume":"158","author":"Asdourian","year":"2022","journal-title":"JAMA Dermatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.12788\/cutis.0011","article-title":"Anti-PD1 immune checkpoint inhibitor-induced bullous pemphigoid in metastatic melanoma and non-small cell lung cancer","volume":"105","author":"Schwartzman","year":"2020","journal-title":"Cutis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/ijd.13984","article-title":"A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors","volume":"57","author":"Lopez","year":"2018","journal-title":"Int J Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"588582","DOI":"10.3389\/fimmu.2020.588582","article-title":"Retrospective analysis of checkpoint inhibitor therapy-associated cases of bullous pemphigoid from six german dermatology centers","volume":"11","author":"Sadik","year":"2020","journal-title":"Front Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"Cd002292","DOI":"10.1002\/14651858.CD002292.pub3","article-title":"Interventions for bullous pemphigoid","volume":"2010","author":"Kirtschig","year":"2010","journal-title":"Cochrane Database Syst Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00403-017-1772-x","article-title":"Mortality in bullous pemphigoid and prognostic factors in 1st and 3rd year of follow-up in specialized centre in Poland","volume":"309","author":"Kalinska-Bienias","year":"2017","journal-title":"Arch Dermatol Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/bjd.19022","article-title":"Incidence, prevalence and mortality of bullous pemphigoid in England 1998-2017: a population-based cohort study","volume":"184","author":"Persson","year":"2021","journal-title":"Br J Dermatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jamadermatol.2020.5598","article-title":"Mixed individual-aggregate data on all-cause mortality in bullous pemphigoid: a meta-analysis","volume":"157","author":"Tedbirt","year":"2021","journal-title":"JAMA Dermatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00403-017-1736-1","article-title":"Prognostic factors for mortality in patients with bullous pemphigoid: a meta-analysis","volume":"309","author":"Liu","year":"2017","journal-title":"Arch Dermatol Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3389\/fmed.2018.00201","article-title":"The role of eosinophils in bullous pemphigoid: a developing model of eosinophil pathogenicity in mucocutaneous disease","volume":"5","author":"Amber","year":"2018","journal-title":"Front Med (Lausanne)."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.3390\/jcm11102856","article-title":"A review of the immunologic pathways involved in bullous pemphigoid and novel therapeutic targets","volume":"11","author":"Afarideh","year":"2022","journal-title":"J Clin Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.jaci.2020.02.013","article-title":"Autoimmune bullous skin diseases, pemphigus and pemphigoid","volume":"145","author":"Egami","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40257-017-0264-2","article-title":"Bullous pemphigoid: a review of its diagnosis, associations and treatment","volume":"18","author":"Bernard","year":"2017","journal-title":"Am J Clin Dermatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.3389\/fimmu.2017.01752","article-title":"BP180 is critical in the autoimmunity of bullous pemphigoid","volume":"8","author":"Liu","year":"2017","journal-title":"Front Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/1523-1747.ep12876194","article-title":"Two groups of bullous pemphigoid antigens are identified by affinity-purified antibodies","volume":"94","author":"Meyer","year":"1990","journal-title":"J Invest Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00441-015-2216-6","article-title":"Molecular architecture and function of the hemidesmosome","volume":"360","author":"Walko","year":"2015","journal-title":"Cell Tissue Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/1346-8138.13207","article-title":"Bullous pemphigoid: What's ahead?","volume":"43","author":"Furue","year":"2016","journal-title":"J Dermatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.jid.2020.08.031","article-title":"Autoantibodies to BPAG1e trigger experimental bullous pemphigoid in mice","volume":"141","author":"Makita","year":"2021","journal-title":"J Invest Dermatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"5742","DOI":"10.4049\/jimmunol.151.10.5742","article-title":"Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain","volume":"151","author":"Giudice","year":"1993","journal-title":"J Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S0923-1811(02)00109-3","article-title":"BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid","volume":"30","author":"Kobayashi","year":"2002","journal-title":"J Dermatol Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1172\/JCI116856","article-title":"A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180","volume":"92","author":"Liu","year":"1993","journal-title":"J Clin Invest."},{"key":"B40","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nm1496","article-title":"Humanization of autoantigen","volume":"13","author":"Nishie","year":"2007","journal-title":"Nat Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1001\/archderm.136.2.174","article-title":"Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid","volume":"136","author":"Schmidt","year":"2000","journal-title":"Arch Dermatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/sj.jid.5602955","article-title":"Detection of IgG autoantibodies in the sera of patients with bullous and gestational pemphigoid: ELISA studies utilizing a baculovirus-encoded form of bullous pemphigoid antigen 2","volume":"110","author":"Haase","year":"1998","journal-title":"J Invest Dermatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamadermatol.2013.5757","article-title":"Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study","volume":"150","author":"Fichel","year":"2014","journal-title":"JAMA Dermatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1038\/jid.2011.180","article-title":"Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study","volume":"131","author":"Di Zenzo","year":"2011","journal-title":"J Invest Dermatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1001\/jamadermatol.2017.5465","article-title":"Clinical and immunological profiles of 14 patients with bullous pemphigoid without IgG autoantibodies to the BP180 NC16A domain","volume":"154","author":"Nakama","year":"2018","journal-title":"JAMA Dermatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1172\/JCI117826","article-title":"The role of complement in experimental bullous pemphigoid","volume":"95","author":"Liu","year":"1995","journal-title":"J Clin Invest."},{"key":"B47","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.4049\/jimmunol.155.11.5449","article-title":"Molecular mapping of a pathogenically relevant BP180 epitope associated with experimentally induced murine bullous pemphigoid","volume":"155","author":"Liu","year":"1995","journal-title":"J Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1172\/JCI3693","article-title":"A critical role for neutrophil elastase in experimental bullous pemphigoid","volume":"105","author":"Liu","year":"2000","journal-title":"J Clin Invest."},{"key":"B49","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00403-007-0790-5","article-title":"Experimental models for the autoimmune and inflammatory blistering disease, Bullous pemphigoid","volume":"299","author":"Leighty","year":"2007","journal-title":"Arch Dermatol Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1172\/JCI119639","article-title":"A major role for neutrophils in experimental bullous pemphigoid","volume":"100","author":"Liu","year":"1997","journal-title":"J Clin Invest."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1172\/JCI11494","article-title":"Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid","volume":"108","author":"Chen","year":"2001","journal-title":"J Clin Invest."},{"key":"B52","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/bjd.14822","article-title":"Complement in bullous pemphigoid: results from a large observational study","volume":"176","author":"Romeijn","year":"2017","journal-title":"Br J Dermatol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/jid.2008.305","article-title":"IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment","volume":"129","author":"Iwata","year":"2009","journal-title":"J Invest Dermatol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.4049\/jimmunol.1400095","article-title":"Bullous pemphigoid autoantibodies directly induce blister formation without complement activation","volume":"193","author":"Ujiie","year":"2014","journal-title":"J Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.4049\/jimmunol.1003402","article-title":"Antibodies to pathogenic epitopes on type XVII collagen cause skin fragility in a complement-dependent and -independent manner","volume":"188","author":"Natsuga","year":"2012","journal-title":"J Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/bjd.14411","article-title":"Bullous pemphigoid suggestive of complement-independent blister formation with anti-BP180 IgG4 autoantibodies","volume":"175","author":"Dainichi","year":"2016","journal-title":"Br J Dermatol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.ajpath.2012.11.029","article-title":"Bullous pemphigoid IgG induces BP180 internalization via a macropinocytic pathway","volume":"182","author":"Hiroyasu","year":"2013","journal-title":"Am J Pathol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"553","DOI":"10.4049\/jimmunol.1001753","article-title":"FcR-independent effects of IgE and IgG autoantibodies in bullous pemphigoid","volume":"187","author":"Messingham","year":"2011","journal-title":"J Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"973702","DOI":"10.3389\/fimmu.2022.973702","article-title":"The relevance of complement in pemphigoid diseases: A critical appraisal","volume":"13","author":"Papara","year":"2022","journal-title":"Front Immunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1586\/1744666X.2016.1123092","article-title":"IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases","volume":"12","author":"van Beek","year":"2016","journal-title":"Expert Rev Clin Immunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1067\/mjd.2000.103986","article-title":"IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity","volume":"42","author":"D\u00f6pp","year":"2000","journal-title":"J Am Acad Dermatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.0022-202X.2005.23853.x","article-title":"Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid","volume":"125","author":"Fairley","year":"2005","journal-title":"J Invest Dermatol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/bjd.15114","article-title":"Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid","volume":"177","author":"Hashimoto","year":"2017","journal-title":"Br J Dermatol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamadermatol.2016.3357","article-title":"Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity","volume":"153","author":"van Beek","year":"2017","journal-title":"JAMA Dermatol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1038\/sj.jid.5700958","article-title":"pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu\/nu mice","volume":"127","author":"Fairley","year":"2007","journal-title":"J Invest Dermatol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/sj.jid.5700681","article-title":"IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice","volume":"127","author":"Zone","year":"2007","journal-title":"J Invest Dermatol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1046\/j.1523-1747.2003.12146.x","article-title":"Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid","volume":"120","author":"Dimson","year":"2003","journal-title":"J Invest Dermatol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/hyb.2011.0102","article-title":"Functional characterization of an IgE-class monoclonal antibody specific for the bullous pemphigoid autoantigen, BP180","volume":"31","author":"Messingham","year":"2012","journal-title":"Hybridoma (Larchmt)."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/bjd.16679","article-title":"Peripheral eosinophilia in bullous pemphigoid: prevalence and influence on the clinical manifestation","volume":"179","author":"Kridin","year":"2018","journal-title":"Br J Dermatol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.1038\/s41598-017-04687-5","article-title":"Eosinophil Cationic Protein (ECP), a predictive marker of bullous pemphigoid severity and outcome","volume":"7","author":"Giusti","year":"2017","journal-title":"Sci Rep."},{"key":"B71","first-page":"897","article-title":"Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins","volume":"148","author":"Borrego","year":"1996","journal-title":"Am J Pathol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/all.13131","article-title":"Evidence for a role of eosinophils in blister formation in bullous pemphigoid","volume":"72","author":"de Graauw","year":"2017","journal-title":"Allergy."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jid.2017.11.031","article-title":"Eosinophils mediate tissue injury in the autoimmune skin disease bullous pemphigoid","volume":"138","author":"Lin","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.matbio.2011.09.003","article-title":"Neutrophil elastase cleaves the murine hemidesmosomal protein BP180\/type XVII collagen and generates degradation products that modulate experimental bullous pemphigoid","volume":"31","author":"Lin","year":"2012","journal-title":"Matrix Biol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/jdv.12464","article-title":"Eosinophil cationic protein levels parallel coagulation activation in the blister fluid of patients with bullous pemphigoid","volume":"29","author":"Tedeschi","year":"2015","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1172\/JCI117196","article-title":"92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen","volume":"93","author":"St\u00e5hle-B\u00e4ckdahl","year":"1994","journal-title":"J Clin Invest."},{"key":"B77","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1165\/ajrcmb.17.4.2877","article-title":"Migration of eosinophils through basement membrane components in vitro: role of matrix metalloproteinase-9","volume":"17","author":"Okada","year":"1997","journal-title":"Am J Respir Cell Mol Biol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1172\/JCI3335","article-title":"Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls","volume":"102","author":"B\u00fcdinger","year":"1998","journal-title":"J Clin Invest."},{"key":"B79","doi-asserted-by":"publisher","first-page":"569287","DOI":"10.3389\/fimmu.2021.569287","article-title":"Autoreactive peripheral blood T helper cell responses in bullous pemphigoid and elderly patients with pruritic disorders","volume":"12","author":"Didona","year":"2021","journal-title":"Front Immunol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/BF02507102","article-title":"Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid","volume":"288","author":"Schmidt","year":"1996","journal-title":"Arch Dermatol Res."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1046\/j.0022-202x.2001.01505.x","article-title":"Skin-homing interleukin-4 and\u221213-producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin-10-producing cells","volume":"117","author":"Teraki","year":"2001","journal-title":"J Invest Dermatol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1046\/j.1365-2133.2000.03599.x","article-title":"Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia","volume":"143","author":"Wakugawa","year":"2000","journal-title":"Br J Dermatol."},{"key":"B83","first-page":"27","article-title":"Increased expression of eotaxin and its specific receptor CCR3 in bullous pemphigoid","volume":"12","author":"Frezzolini","year":"2002","journal-title":"Eur J Dermatol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.clim.2006.03.014","article-title":"Increased expression of Th2-associated chemokines in bullous pemphigoid disease. Role of eosinophils in the production and release of these chemokines","volume":"120","author":"Gounni Abdelilah","year":"2006","journal-title":"Clin Immunol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/j.1365-2133.2006.07305.x","article-title":"Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris","volume":"155","author":"Asashima","year":"2006","journal-title":"Br J Dermatol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jdermsci.2006.12.008","article-title":"Increased serum levels of a proliferation-inducing ligand in patients with bullous pemphigoid","volume":"46","author":"Watanabe","year":"2007","journal-title":"J Dermatol Sci."},{"key":"B87","doi-asserted-by":"publisher","first-page":"766","DOI":"10.2340\/00015555-2951","article-title":"Eosinophils are a major source of interleukin-31 in bullous pemphigoid","volume":"98","author":"R\u00fcdrich","year":"2018","journal-title":"Acta Derm Venereol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/s0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","volume":"389","author":"Williams","year":"2017","journal-title":"Lancet."},{"key":"B89","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1182\/blood.V83.2.435.bloodjournal832435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood."},{"key":"B90","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/bjd.13633","article-title":"First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid","volume":"173","author":"Cho","year":"2015","journal-title":"Br J Dermatol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fimmu.2018.00248","article-title":"Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases","volume":"9","author":"Lamberts","year":"2018","journal-title":"Front Immunol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jaad.2019.11.023","article-title":"Clinical outcome and safety of rituximab therapy for pemphigoid diseases","volume":"82","author":"Tovanabutra","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1038\/jid.2013.236","article-title":"Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients","volume":"133","author":"Hall","year":"2013","journal-title":"J Invest Dermatol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/ckj\/sfx038","article-title":"Infectious complications of rituximab therapy in renal disease","volume":"10","author":"Nixon","year":"2017","journal-title":"Clin Kidney J."},{"key":"B95","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1939-4551-7-17","article-title":"New strategies with anti-IgE in allergic diseases","volume":"7","author":"Holgate","year":"2014","journal-title":"World Allergy Organ J."},{"key":"B96","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s12016-015-8490-y","article-title":"Off-label uses of omalizumab","volume":"50","author":"El-Qutob","year":"2016","journal-title":"Clin Rev Allergy Immunol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaci.2008.11.035","article-title":"Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab","volume":"123","author":"Fairley","year":"2009","journal-title":"J Allergy Clin Immunol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.3389\/fimmu.2019.01919","article-title":"Effects of Omalizumab on Fc\u03b5RI and IgE expression in lesional skin of bullous pemphigoid","volume":"10","author":"Seyed Jafari","year":"2019","journal-title":"Front Immunol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jdcr.2020.01.002","article-title":"Increasing evidence for omalizumab in the treatment of bullous pemphigoid","volume":"6","author":"Lonowski","year":"2020","journal-title":"JAAD Case Rep."},{"key":"B100","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1177\/12034754221089267","article-title":"Omalizumab for the treatment of bullous pemphigoid: a systematic review of efficacy and safety","volume":"26","author":"D'Aguanno","year":"2022","journal-title":"J Cutan Med Surg."},{"key":"B101","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin Exp Allergy."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2217\/imt-2020-0175","article-title":"Dupilumab use in atopic dermatitis and beyond in skin diseases","volume":"12","author":"Fourzali","year":"2020","journal-title":"Immunotherapy."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the treatment of recalcitrant bullous pemphigoid","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series","volume":"83","author":"Abdat","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"e15648","DOI":"10.1111\/dth.15648","article-title":"Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid","volume":"35","author":"Yang","year":"2022","journal-title":"Dermatol Ther."},{"key":"B106","doi-asserted-by":"publisher","first-page":"738907","DOI":"10.3389\/fimmu.2021.738907","article-title":"Efficacy and safety of dupilumab in moderate-to-severe bullous pemphigoid","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/1346-8138.16428","article-title":"Treatment of bullous pemphigoid with dupilumab: Dupilumab exerts its effect by primarily suppressing T-helper 2 cytokines","volume":"49","author":"Takamura","year":"2022","journal-title":"J Dermatol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"928621","DOI":"10.3389\/fimmu.2022.928621","article-title":"Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review","volume":"13","author":"Cao","year":"2022","journal-title":"Front Immunol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40257-018-0401-6","article-title":"Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature","volume":"20","author":"Kremer","year":"2019","journal-title":"Am J Clin Dermatol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"629","DOI":"10.4049\/jimmunol.149.2.629","article-title":"Release of granule proteins from eosinophils cultured with IL-5","volume":"149","author":"Kita","year":"1992","journal-title":"J Immunol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s004030050272","article-title":"IL-5 levels in the serum and blister fluid of patients with bullous pemphigoid: correlations with eosinophil cationic protein, RANTES, IgE and disease severity","volume":"290","author":"D'Auria","year":"1998","journal-title":"Arch Dermatol Res."},{"key":"B112","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1006\/cyto.2000.0791","article-title":"Bullous pemphigoid: interaction of interleukin 5, anti-basement membrane zone antibodies and eosinophils. A preliminary observation","volume":"13","author":"Engineer","year":"2001","journal-title":"Cytokine."},{"key":"B113","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13223-021-00619-1","article-title":"Successful induction treatment of bullous pemphigoid using reslizumab: a case report","volume":"17","author":"Rhyou","year":"2021","journal-title":"Allergy Asthma Clin Immunol."},{"key":"B114","unstructured":"Anti-IL-5 Therapy in Bullous Pemphigoid (BP)"},{"key":"B115","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/all.13950","article-title":"Mepolizumab failed to affect bullous pemphigoid: A randomized, placebo-controlled, double-blind phase 2 pilot study","volume":"75","author":"Simon","year":"2020","journal-title":"Allergy."},{"key":"B116","unstructured":""},{"key":"B117","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2249.2011.04464.x","article-title":"Up-regulation of CCL11 and CCL26 is associated with activated eosinophils in bullous pemphigoid","volume":"166","author":"G\u00fcnther","year":"2011","journal-title":"Clin Exp Immunol."},{"key":"B118","unstructured":""},{"key":"B119","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3389\/fimmu.2019.00978","article-title":"Current Clinical Trials in Pemphigus and Pemphigoid","volume":"10","author":"Izumi","year":"2019","journal-title":"Front Immunol."},{"key":"B120","unstructured":""},{"key":"B121","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jaut.2012.07.004","article-title":"The role of Th17\/IL-17 on eosinophilic inflammation","volume":"40","author":"Dias","year":"2013","journal-title":"J Autoimmun."},{"key":"B122","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1038\/jid.2014.263","article-title":"Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid","volume":"134","author":"Le Jan","year":"2014","journal-title":"J Invest Dermatol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"e1006175","DOI":"10.1371\/journal.ppat.1006175","article-title":"Central Role of IL-23 and IL-17 producing eosinophils as immunomodulatory effector cells in acute pulmonary aspergillosis and allergic asthma","volume":"13","author":"Guerra","year":"2017","journal-title":"PLoS Pathog."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1172\/JCI28508","article-title":"The IL-23\/IL-17 axis in inflammation","volume":"116","author":"Iwakura","year":"2006","journal-title":"J Clin Invest."},{"key":"B125","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaut.2018.09.003","article-title":"IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid","volume":"96","author":"Chakievska","year":"2019","journal-title":"J Autoimmun"},{"key":"B126","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1111\/ajd.13803","article-title":"Successful secukinumab treatment of active bullous pemphigoid and chronic severe psoriasis: a case report","volume":"63","author":"Yun","year":"2022","journal-title":"Australas J Dermatol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1111\/1346-8138.14760","article-title":"Secukinumab decreased circulating anti-BP180-NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid","volume":"46","author":"Kamata","year":"2019","journal-title":"J Dermatol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1111\/1346-8138.16189","article-title":"Incidental amelioration of bullous pemphigoid during ixekizumab treatment for psoriasis","volume":"49","author":"Lu","year":"2022","journal-title":"J Dermatol."},{"key":"B129","unstructured":""},{"key":"B130","unstructured":""},{"key":"B131","unstructured":""},{"key":"B132","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/ddg.14668","article-title":"JAK-inhibitors in dermatology - small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects","volume":"20","author":"Klein","year":"2022","journal-title":"J Dtsch Dermatol Ges."},{"key":"B133","first-page":"4","article-title":"Janus kinase and tyrosine kinase inhibitors in dermatology: a review of their utilization, safety profile and future applications","volume":"27","author":"Shalabi","year":"2022","journal-title":"Skin Therapy Lett."},{"key":"B134","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jaad.2021.07.002","article-title":"Janus kinase inhibitors in dermatology: Part I. A comprehensive review","volume":"86","author":"Chapman","year":"2022","journal-title":"J Am Acad Dermatol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs. dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"e15754","DOI":"10.1111\/dth.15754","article-title":"Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib","volume":"35","author":"Xiao","year":"2022","journal-title":"Dermatol Ther."},{"key":"B137","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jdcr.2022.12.006","article-title":"Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib","volume":"32","author":"Nash","year":"2023","journal-title":"JAAD Case Rep."},{"key":"B138","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdcr.2022.10.028","article-title":"Two cases of bullous pemphigoid effectively treated with oral tofacitinib","volume":"32","author":"Youssef","year":"2023","journal-title":"JAAD Case Rep."},{"key":"B139","unstructured":""},{"key":"B140","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet."},{"key":"B141","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science."},{"key":"B142","unstructured":""},{"key":"B143","doi-asserted-by":"publisher","first-page":"1057096","DOI":"10.3389\/fmed.2022.1057096","article-title":"Bullous pemphigoid-What do we know about the most recent therapies?","volume":"9","author":"Zeng","year":"2022","journal-title":"Front Med (Lausanne)."},{"key":"B144","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40257-021-00597-5","article-title":"Effectiveness and safety of long-term dupilumab treatment in elderly patients with atopic dermatitis: a multicenter real-life observational study","volume":"22","author":"Patruno","year":"2021","journal-title":"Am J Clin Dermatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1196946\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T11:03:33Z","timestamp":1691492613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1196946\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,8]]},"references-count":144,"alternative-id":["10.3389\/fmed.2023.1196946"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1196946","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,8]]},"article-number":"1196946"}}